Recommends

Mehmet Oz on most-favored-nation drug pricing: recommends

Dr. Mehmet Oz recommends most-favored-nation (MFN) drug pricing — benchmarking U.S. prices for branded drugs against the lower prices manufacturers accept in other developed countries — and has made codifying the administration’s MFN deals one of his recurring public asks of Congress. The deals underpin the TrumpRx.gov direct-purchase platform and the pricing structure behind the Medicare GLP-1 Bridge.

Oz’s stated reasoning is that Americans should not pay more than patients abroad for the same medicines, and that the negotiated deals produced what he called, in a September 9, 2026 Bloomberg Television interview, the largest drop in consumer pharmaceutical prices in 63 years — crediting agreements with the top 26 pharmaceutical companies covering 90% of branded drugs sold in drugstores. Because the contracts expire at the end of the administration, he argues Congress should write MFN pricing into law; he repeated the codification call at an April 28, 2026 Paragon Health Institute discussion, describing it as an idea with bipartisan appeal.

Supporters, including the President and administration officials, present MFN as the fastest available lever on list prices. Critics — including pharmaceutical manufacturers and some health economists — argue reference pricing distorts global launch decisions, that the deals’ net savings depend on confidential terms, and that codification would convert a negotiating tactic into a rigid formula. The deals themselves are tracked on Oz’s most-favored-nation drug pricing initiative page; this page tracks his stand in favor of them.

This page chronicles a stated position of the person above. It is not medical advice and not the site's own conclusion.

The Weekly Scoreboard

Every Friday: what the RFK Jr. HHS team did this week — wins, setbacks, warnings — sourced and linked. Free.

One email a week. No spam. Unsubscribe anytime. · Follow on Facebook

The Network — One Publisher, Every Front
Published by Bowman Web Services.